The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…
Search results for: polyarticular arthritis
3 Ways to Advance the Med-Peds Role in Rheumatology
Research into training and careers for Med-Peds—internal medicine-pediatrics trained rheumatologists–will help pinpoint how this unique specialty can support patient needs and address rheumatology workforce shortages…
No Evidence to Support Biologic Switching Guidelines for JIA
NEW YORK (Reuters Health)—For young people with juvenile idiopathic arthritis (JIA) who don’t achieve disease control, switching to a different class of biologic is unlikely to be beneficial, researchers say. The observational study yielded no evidence to support or refute the 2015 National Health Service England guidelines, which recommend switching most patients to a second…
Pediatric Cases Require Special Considerations & Aggressive Treatment Plans
ATLANTA—Managing pediatric patients with rheumatic disease involves special considerations, such as developmental concerns and physiological traits that may affect dosing of medications, according to two experts. During a session at the 2019 ACR/ARP Annual Meeting, Courtney Kremer, ARNP, a pediatric nurse practitioner at the University of Iowa Stead Family Children’s Hospital, Iowa City, and Jessica…
FDA Update: New Drug Approvals, New & Expanded Indications, & More
ATLANTA—New drug approvals, new and expanded drug indications, and important safety and other updates relevant for rheumatologists were presented by three physicians from the U.S. Food & Drug Administration (FDA) on Nov. 11 at the 2019 ACR/ARP Annual Meeting. New JAK Inhibitor Approved for RA On Aug. 16, 2019, the FDA approved upadacitinib (Rinvoq), an…
Thoughtful Pediatric Care: Pediatric Cases Require Special Considerations & Aggressive Treatment Plans
In Canada, five provinces will now reimburse patients with plaque psoriasis who use risankizumab. Also, Canada Health has approved apremilast for treating adults with plaque psoriasis and psoriatic arthritis…
FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns
Last year, the FDA was busy with new biologic and other drug approvals, new and expanded drug indications, and important safety updates relevant to rheumatology…
Tips for Engaging Your Pediatric Research Patients
ATLANTA—Around 2002, when Vincent Del Gaizo’s son was just 15 months old, he was hospitalized in an intensive care unit and, weeks later, was diagnosed with systemic juvenile idiopathic arthritis (JIA). “We had the same 8 trillion questions that all parents have when their child is diagnosed with a condition you’ve never heard of: ‘Is…
The 2019 ACR Award Winners & Distinguished Fellows
ATLANTA—Every year at its Annual Meeting, the ACR recognizes its members’ outstanding contributions to the field of rheumatology through an awards program. The ACR is proud to announce 20 award recipients for 2019, honored for their accomplishments as clinicians, instructors or researchers who have helped advance rheumatology, for their commitment to inspire others to enter…
Case Report: Not All Crystals Are Gout
Patients with chronic kidney disease (CKD) often experience joint pain due to various etiologies, including crystalline arthropathies, renal osteodystrophy, amyloid arthropathy, erosive osteoarthritis, avascular necrosis and even erosive spondylarthrosis.1 Below, we present a case of crystalline arthropathy in a patient with chronic kidney disease, mistaken for gout. The Case A 29-year-old man was admitted to…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 13
- Next Page »